Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments
Abstract Breast cancer (BC) is the most common cancer occurring in women but also rarely develops in men. Recent advances in early diagnosis and development of targeted therapies have greatly improved the survival rate of BC patients. However, the basal-like BC subtype (BLBC), largely overlapping wi...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/20c0c3f49a9e491b86d9b16315f3a86d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:20c0c3f49a9e491b86d9b16315f3a86d |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:20c0c3f49a9e491b86d9b16315f3a86d2021-12-05T12:04:31ZDecreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments10.1038/s41419-021-04407-y2041-4889https://doaj.org/article/20c0c3f49a9e491b86d9b16315f3a86d2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41419-021-04407-yhttps://doaj.org/toc/2041-4889Abstract Breast cancer (BC) is the most common cancer occurring in women but also rarely develops in men. Recent advances in early diagnosis and development of targeted therapies have greatly improved the survival rate of BC patients. However, the basal-like BC subtype (BLBC), largely overlapping with the triple-negative BC subtype (TNBC), lacks such drug targets and conventional cytotoxic chemotherapies often remain the only treatment option. Thus, the development of resistance to cytotoxic therapies has fatal consequences. To assess the involvement of epigenetic mechanisms and their therapeutic potential increasing cytotoxic drug efficiency, we combined high-throughput RNA- and ChIP-sequencing analyses in BLBC cells. Tumor cells surviving chemotherapy upregulated transcriptional programs of epithelial-to-mesenchymal transition (EMT) and stemness. To our surprise, the same cells showed a pronounced reduction of polycomb repressive complex 2 (PRC2) activity via downregulation of its subunits Ezh2, Suz12, Rbbp7 and Mtf2. Mechanistically, loss of PRC2 activity leads to the de-repression of a set of genes through an epigenetic switch from repressive H3K27me3 to activating H3K27ac mark at regulatory regions. We identified Nfatc1 as an upregulated gene upon loss of PRC2 activity and directly implicated in the transcriptional changes happening upon survival to chemotherapy. Blocking NFATc1 activation reduced epithelial-to-mesenchymal transition, aggressiveness, and therapy resistance of BLBC cells. Our data demonstrate a previously unknown function of PRC2 maintaining low Nfatc1 expression levels and thereby repressing aggressiveness and therapy resistance in BLBC.Iga K. MieczkowskaGaryfallia Pantelaiou-ProkakiEvangelos ProkakisGeske E. SchmidtLukas C. Müller-KirschbaumMarcel WernerMadhobi SenTaras VelychkoKatharina JannaschChristian DullinJoanna NappKlaus PantelHarriet WikmanMaria WieseChristof M. KrammFrauke AlvesFlorian WegwitzNature Publishing GrouparticleCytologyQH573-671ENCell Death and Disease, Vol 12, Iss 12, Pp 1-13 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Cytology QH573-671 |
spellingShingle |
Cytology QH573-671 Iga K. Mieczkowska Garyfallia Pantelaiou-Prokaki Evangelos Prokakis Geske E. Schmidt Lukas C. Müller-Kirschbaum Marcel Werner Madhobi Sen Taras Velychko Katharina Jannasch Christian Dullin Joanna Napp Klaus Pantel Harriet Wikman Maria Wiese Christof M. Kramm Frauke Alves Florian Wegwitz Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments |
description |
Abstract Breast cancer (BC) is the most common cancer occurring in women but also rarely develops in men. Recent advances in early diagnosis and development of targeted therapies have greatly improved the survival rate of BC patients. However, the basal-like BC subtype (BLBC), largely overlapping with the triple-negative BC subtype (TNBC), lacks such drug targets and conventional cytotoxic chemotherapies often remain the only treatment option. Thus, the development of resistance to cytotoxic therapies has fatal consequences. To assess the involvement of epigenetic mechanisms and their therapeutic potential increasing cytotoxic drug efficiency, we combined high-throughput RNA- and ChIP-sequencing analyses in BLBC cells. Tumor cells surviving chemotherapy upregulated transcriptional programs of epithelial-to-mesenchymal transition (EMT) and stemness. To our surprise, the same cells showed a pronounced reduction of polycomb repressive complex 2 (PRC2) activity via downregulation of its subunits Ezh2, Suz12, Rbbp7 and Mtf2. Mechanistically, loss of PRC2 activity leads to the de-repression of a set of genes through an epigenetic switch from repressive H3K27me3 to activating H3K27ac mark at regulatory regions. We identified Nfatc1 as an upregulated gene upon loss of PRC2 activity and directly implicated in the transcriptional changes happening upon survival to chemotherapy. Blocking NFATc1 activation reduced epithelial-to-mesenchymal transition, aggressiveness, and therapy resistance of BLBC cells. Our data demonstrate a previously unknown function of PRC2 maintaining low Nfatc1 expression levels and thereby repressing aggressiveness and therapy resistance in BLBC. |
format |
article |
author |
Iga K. Mieczkowska Garyfallia Pantelaiou-Prokaki Evangelos Prokakis Geske E. Schmidt Lukas C. Müller-Kirschbaum Marcel Werner Madhobi Sen Taras Velychko Katharina Jannasch Christian Dullin Joanna Napp Klaus Pantel Harriet Wikman Maria Wiese Christof M. Kramm Frauke Alves Florian Wegwitz |
author_facet |
Iga K. Mieczkowska Garyfallia Pantelaiou-Prokaki Evangelos Prokakis Geske E. Schmidt Lukas C. Müller-Kirschbaum Marcel Werner Madhobi Sen Taras Velychko Katharina Jannasch Christian Dullin Joanna Napp Klaus Pantel Harriet Wikman Maria Wiese Christof M. Kramm Frauke Alves Florian Wegwitz |
author_sort |
Iga K. Mieczkowska |
title |
Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments |
title_short |
Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments |
title_full |
Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments |
title_fullStr |
Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments |
title_full_unstemmed |
Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments |
title_sort |
decreased prc2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments |
publisher |
Nature Publishing Group |
publishDate |
2021 |
url |
https://doaj.org/article/20c0c3f49a9e491b86d9b16315f3a86d |
work_keys_str_mv |
AT igakmieczkowska decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT garyfalliapantelaiouprokaki decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT evangelosprokakis decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT geskeeschmidt decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT lukascmullerkirschbaum decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT marcelwerner decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT madhobisen decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT tarasvelychko decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT katharinajannasch decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT christiandullin decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT joannanapp decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT klauspantel decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT harrietwikman decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT mariawiese decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT christofmkramm decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT fraukealves decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments AT florianwegwitz decreasedprc2activitysupportsthesurvivalofbasallikebreastcancercellstocytotoxictreatments |
_version_ |
1718372241590190080 |